Rad53 was initially identified in 1991 [3] in a biochemical screen as a serine/threonine/tyrosine kinase, but became soon known as a key guardian of genome integrity [4]. We now know that the Rad53 family members, which include the Chk2 protein in human cells, play a central role in the signal transduction pathway that is activated in response to DNA lesions and helps to prevent genome rearrangements and cancer [5].
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Phospho-residues according to Sweeney et al. [2] Phospho-residues according to Smolka et Impressively, the Rad53 protein turns out to be phosphorylated at more than twenty residues (Figure 1 ) and, whereas a number of them are generated by autophosphorylation events, as demonstrated by Sweeney et al. Considering that Rad53 and Rad9 are phosphorylated at multiple sites, the two models for Rad53 activation may not be necessarily exclusive (Figure 2A,B) and could be reconciled in a stepwise model in which Rad9 acts both as an adaptor mediating the interaction between Mec1 and Rad53 and as a scaffold protein facilitating the concentration of Rad53 molecules ( Figure 2C ).
Once again, phosphorylation at multiple sites emerges as a common strategy in kinase-based signal transduction processes. This mechanism of activation, in theory, would be ideal to avoid futile activation of the pathway when the signal is below a certain threshold. Further, the redundancy of phospho-sites represents a warranty for the cell against mutations on those residues, as the inactivation of one of these sites should not necessarily impair the transduction cascade.
